Pine Valley Investments buys stake in Novo Nordisk amid Wegovy competition
Pine Valley Investments Ltd Liability Co added shares of Novo Nordisk in the second quarter, per its latest SEC 13F filing. Revolve Wealth and Sivia Capital also increased their holdings. Sentiment is mixed: oral Wegovy adoption is viewed as a possible catalyst, but Eli Lilly’s obesity-drug gains and an escalating marketing dispute raise competitive concerns despite Novo’s record oral Wegovy prescriptions. Weiss Ratings upgraded Novo to hold.